We searched Medline and PubMed for reviews and original articles about pulmonary alveolar proteinosis published in English from Jan 1, 1950, to July 1, 2017. We used the terms “pulmonary alveolar proteinosis” in combination with “pathogenesis”, “diagnosis” and “treatment”. We also searched individual terms such as “GM-CSF”, “alveolar macrophages”, “whole lung lavage”, “recombinant GM-CSF”, “rituximab”, “plasmapheresis”, and “lung transplantation”. We chose studies mostly published within the
ReviewPulmonary alveolar proteinosis in adults: pathophysiology and clinical approach
Introduction
Since its first description in 1958 by Rosen and colleagues,1 our understanding of the pathogenesis, natural history, and treatment of pulmonary alveolar proteinosis (PAP) has evolved considerably. PAP is characterised by the accumulation of surfactant in alveolar macrophages and alveoli, resulting in impaired gas exchange. Clinically, patients with PAP can be asymptomatic or present with progressive dyspnoea, worsening oxygen requirements, and have an increased susceptibility to infections. PAP has a variable clinical course, ranging from spontaneous resolution to death from infections or progressive respiratory failure. In this Review, we elucidate current knowledge of the pathogenesis of PAP, and also discuss the diagnosis, treatment, and future developments.
Section snippets
Pathogenesis and classification of PAP
The principal abnormalities in adult PAP result from poor surfactant clearance and altered surfactant homoeostasis in the lung due to impaired alveolar macrophage function (figure 1). Attenuated alveolar macrophage maturation is typically caused by inadequate granulocyte–macrophage colony-stimulating factor (GM-CSF) signalling, which is crucial for development of the full range of alveolar macrophage metabolic and immune functions.2 Autoimmune PAP, formerly known as idiopathic PAP, occurs when
Role of GM-CSF in PAP
One of the major breakthroughs in our understanding of the pivotal role of GM-CSF for alveolar macrophage function was the near fortuitous discovery that GM-CSF knock-out mice developed intra-alveolar accumulation of surfactants, remarkably similar in phenotype to human PAP.14, 15 Mice deficient in the GM-CSF receptor β chain also developed a lung phenotype similar to that of GM-CSF-deficient mice.16 Replacement of the GM-CSF gene and treatment with aerosolised GM-CSF were found to correct the
Clinical features
PAP typically presents in the third to sixth decade of life.4 The disease is more common in men, with a prevalence ratio of approximately 2:1.4, 8 However, women might have an earlier age of presentation than men.4 There is no known racial predilection. Although a causal relationship between tobacco use or environmental triggers and PAP has not been established, there is a higher than expected proportion of smokers (50–70%) and dust exposure (20–50%) in reported cohorts.4, 8, 41 It is possible
Diagnosis of PAP
Although clinical presentation and HRCT pattern alone can be fairly suggestive in typical cases, the first step in confirming PAP is usually a bronchoscopy. Broncho-alveolar lavage might demonstrate characteristic opalescent or milky-appearing fluid (figure 3). The milky consistency is due to the high lipoproteinaceous content of the amorphous material that accumulates in the alveolar spaces. Under light microscopy, characteristic acellular oval bodies that are basophilic on May–Grünwald–Giemsa
Treatment
There are no international consensus guidelines for treatment of PAP. Conventionally, therapeutic decisions are largely based on disease severity and type of PAP. Patients with mild symptoms and no evidence of substantial physiological impairment can be monitored by serial assessment of symptoms, pulmonary function testing, oxygenation, and chest radiography. Patients with moderate-to-severe disease warrant a more aggressive approach. Similar to recommendations for patients with other chronic
Corticosteroids
By analogy with other autoimmune diseases, corticosteroid therapy seems logical for treatment of autoimmune PAP. However, most data from patients with PAP treated with corticosteroids suggest more harm than benefit. In a retrospective study,82 patients treated with steroids had a dose-dependent worsening of their Disease Severity Scores. Although the exact explanation is unknown, it is likely that the negative effect corticosteroids exert on macrophage phagocytosis and catabolism account for
Lung transplantation
There is minimal experience with lung transplantation in patients with PAP. Recurrence in the lung allograft is one of the major concerns with transplantation in PAP.91, 92, 93 Recurrence in transplant recipients could be attributed to the immune dysregulation that is persistent in patients with PAP, particularly those with underlying genetic mutations.91 Secondary PAP can also develop de novo in some transplant recipients, and is probably related to disruption of the native immune system by
Treatment of hereditary and secondary PAP
For patients with secondary PAP, the initial therapeutic focus should generally be on removing offending exposures or treating the underlying medical disorder. For individuals with myelodysplastic syndrome, the development of PAP is associated with poor survival.99 In patients with advanced respiratory compromise, WLL could be useful.100 Bone-marrow transplantation has been considered in myelodysplastic syndrome complicated by secondary PAP, but the data are limited to case reports.101, 102
Prognosis
The clinical course of PAP is highly variable, ranging from spontaneous resolution to death due to progressive respiratory failure or infection.4 Although observations from early cohorts suggested that spontaneous resolution occurs in 25–30% of patients, more recent studies observed resolution in only 7–8% of patients.4, 103, 104 There are no known reliable clinical features that can predict which patients will have spontaneous remission. In a large study starting in the 1950s by Seymour and
Future research
One of the major impediments to estimating prevalence, ascertaining diagnosis, and defining the actual effect of therapies in PAP is the rarity of the condition. A US registry for patients with PAP is currently recruiting and should provide further insights into the prevalence and genetic risk factors for development of the disease. The registry also aims to demonstrate the feasibility of measuring GM-CSF antibodies with a diagnostic blood spot card (NCT02461615).
The indications and benefits of
Conclusions
Since the original description of PAP, our understanding of the pathogenesis and classification of the disorder have evolved substantially. Impaired alveolar macrophage maturation and surfactant clearance due to abnormal GM-CSF signalling are now recognised as the fundamental defects in autoimmune PAP, which constitutes the majority of adult cases. However, PAP can be secondary to other triggers, particularly bone-marrow disorders or inhalational exposures, and is rarely hereditary. Although
Search strategy and selection criteria
References (115)
- et al.
Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor
FEBS Lett
(1999) - et al.
Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1
Chest
(2013) - et al.
The molecular basis of pulmonary alveolar proteinosis
Clin Immunol
(2010) - et al.
Protein–lipid interactions and surface activity in the pulmonary surfactant system
Chem Phys Lipids
(2006) - et al.
In defense of the lung: surfactant protein A and surfactant protein D
Curr Opin Pharmacol
(2006) - et al.
High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis
Blood
(2004) - et al.
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
J Lipid Res
(2007) - et al.
Targeted PPARγ deficiency in alveolar macrophages disrupts surfactant catabolism
J Lipid Res
(2010) - et al.
The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation
Cell
(2008) - et al.
GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1
Immunity
(2001)
Indium lung disease
Chest
Pulmonary alveolar proteinosis syndrome
Clin Chest Med
Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients
Respir Med
Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis
J Immunol Methods
Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis
Mayo Clin Proc
Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis
Chest
Pulmonary alveolar proteinosis: clinical features and outcomes
Chest
Pulmonary alveolar proteinosis: treatment by bronchofiberscopic lobar lavage
Chest
An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis
Chest
Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis
Clin Immunol
Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy
Chest
Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6
Pulm Pharmacol
Plasmapheresis failure in the treatment of auto-immune pulmonary alveolar proteinosis
Rev Mal Respir
Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB
Respir Med Case Rep
Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance
J Pediatr
Recurrent alveolar proteinosis following double lung transplantation
Chest
Secondary pulmonary alveolar proteinosis in hematologic malignancies
Hematol Oncol Stem Cell Ther
Pulmonary alveolar proteinosis
N Engl J Med
Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy
Am J Respir Crit Care Med
Pulmonary alveolar proteinosis: progress in the first 44 years
Am J Respir Crit Care Med
Alterations in SP-B and SP-C expression in neonatal lung disease
Annu Rev Physiol
Genetic disorders of surfactant dysfunction
Pediatr Dev Pathol
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan
Am J Respir Crit Care Med
Pulmonary surfactant proteins and lipids as modulators of inflammation and innate immunity
Respirology
Clearance and recycling of pulmonary surfactant
Am J Physiol
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis
Science
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology
Proc Natl Acad Sci USA
Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5
Proc Natl Acad Sci USA
Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice
J Clin Invest
Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice
Am J Physiol
PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor
Am J Physiol Lung Cell Mol Physiol
Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor
J Exp Med
Serological diagnosis of idiopathic pulmonary alveolar proteinosis
Am J Respir Crit Care Med
Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates
Am J Respir Crit Care Med
Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis
N Engl J Med
Targeting cholesterol homeostasis in lung diseases
Sci Rep
Role of diminished epithelial GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis
Am J Physiol Lung Cell Mol Physiol
GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism
J Immunol
GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis
N Engl J Med
GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection
J Clin Invest
Cited by (110)
Veno-venal extracorporeal membrane oxygenation to support whole-lung lavage in a severe case of pulmonary alveolar proteinosis
2024, Revista Espanola de Anestesiologia y ReanimacionPulmonary alveolar proteinosis in Taiwan
2023, Journal of the Formosan Medical Association